Menin: A scaffold protein that controls gene expression and cell signaling

Trends in Biochemical Sciences

Volumn 38, Issue 8, 2013, Pages 394-402

  Matkar, Smita ^a   Thiel, Austin ^a   Hua, Xianxin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell signaling; Gene transcription; Menin; Scaffold protein

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; GASTRIN; HOX PROTEIN; HYBRID PROTEIN; LENS EPITHELIUM DERIVED GROWTH FACTOR; MENIN PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE LEUKEMIA PROTEIN; PEPTIDOMIMETIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MLL1; PROTEIN MLL2; RAS PROTEIN; RETINOBLASTOMA BINDING PROTEIN 2; SCAFFOLD PROTEIN; SOMATOSTATIN; STRESS ACTIVATED PROTEIN KINASE; SUMO 1 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR JUND; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CRYSTAL STRUCTURE; DIABETES MELLITUS; GAS1 GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENETIC CODE; HOX GENE; HUMAN; INTRACELLULAR SIGNALING; LEUKEMOGENESIS; MEN1 GENE; MLL1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RBP2 GENE; REVIEW; SUMOYLATION; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY;

CELL SIGNALING; GENE TRANSCRIPTION; MENIN; SCAFFOLD PROTEIN;

ANIMALS; DOWN-REGULATION; ENDOCRINE GLANDS; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; NEOPLASM PROTEINS; NUCLEAR MATRIX; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 84880721384     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2013.05.005     Document Type: Review

References (95)

1. Chandrasekharappa S.C., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276:404-407.
2. Lemmens I., et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum. Mol. Genet. 1997, 6:1177-1183.
3. Agarwal S.K., et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm. Metab. Res. 2005, 37:369-374.
4. Boikos S.A., Stratakis C.A. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Hum. Mol. Genet. 2007, 16:R80-R87.
5. Lemos M.C., Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 2008, 29:22-32.
6. Libe R., Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur. J. Endocrinol. 2005, 153:477-487.
7. Thakker R.V., et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 2012, 97:2990-3011.
8. Agarwal S.K., et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum. Mol. Genet. 1997, 6:1169-1175.
9. Carling T., et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1998, 83:2960-2963.
10. Jiao Y., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203.
11. Bertolino P., et al. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol. 2003, 17:1880-1892.
12. Crabtree J.S., et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1118-1123.
13. Harding B., et al. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr. Relat. Cancer 2009, 16:1313-1327.
14. Guru S.C., et al. Characterization of a MEN1 ortholog from Drosophila melanogaster. Gene 2001, 263:31-38.
15. Guru S.C., et al. Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene. Mamm. Genome 1999, 10:592-596.
16. Stewart C., et al. Characterization of the mouse Men1 gene and its expression during development. Oncogene 1998, 17:2485-2493.
17. Chen Y.X., et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1018-1023.
18. Yokoyama A., et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123:207-218.
19. Wu Y., et al. Interplay between menin and K-Ras in regulating lung adenocarcinoma. J. Biol. Chem. 2012, 287:40003-40011.
20. Gao S.B., et al. Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. Oncogene 2009, 28:4095-4104.
21. Seigne C., et al. Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice. BMC Cancer 2010, 10:395.
22. Seigne C., et al. High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands. J. Pathol. 2013, 229:546-558.
23. Karnik S.K., et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007, 318:806-809.
24. Yang Y., et al. Reversal of preexisting hyperglycemia in diabetic mice by acute deletion of the Men1 gene. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20358-20363.
25. Yang Y., et al. Deletion of the Men1 gene prevents streptozotocin-induced hyperglycemia in mice. Exp. Diabetes Res. 2010, 2010:876701.
26. Aziz A., et al. Menin expression modulates mesenchymal cell commitment to the myogenic and osteogenic lineages. Dev. Biol. 2009, 332:116-130.
27. Hendy G.N., et al. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm. Metab. Res. 2005, 37:375-379.
28. Inoue Y., et al. Menin interacts with beta-catenin in osteoblast differentiation. Horm. Metab. Res. 2011, 43:183-187.
29. Kaji H. Menin and bone metabolism. J. Bone Miner. Metab. 2012, 30:381-387.
30. Naito J., et al. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. J. Biol. Chem. 2005, 280:4785-4791.
31. Sowa H., et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J. Biol. Chem. 2004, 279:40267-40275.
32. Cheng P., et al. Menin prevents liver steatosis through co-activation of peroxisome proliferator-activated receptor alpha. FEBS Lett. 2011, 585:3403-3408.
33. Zindy P.J., et al. Upregulation of the tumor suppressor gene menin in hepatocellular carcinomas and its significance in fibrogenesis. Hepatology 2006, 44:1296-1307.
34. Zhang H., et al. Menin expression is regulated by transforming growth factor beta signaling in leukemia cells. Chin. Med. J. (Engl.) 2011, 124:1556-1562.
35. Canaff L., et al. Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. J. Clin. Endocrinol. Metab. 2012, 97:E282-E291.
36. Feng Z.J., et al. SUMO modification of menin. Am. J. Cancer Res. 2013, 3:96-106.
37. MacConaill L.E., et al. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol. Cancer Res. 2006, 4:793-801.
38. Yaguchi H., et al. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol. Cell. Biol. 2004, 24:6569-6580.
39. Balogh K., et al. Menin and its interacting proteins: elucidation of menin function. Trends Endocrinol. Metab. 2006, 17:357-364.
40. Poisson A., et al. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett. 2003, 189:1-10.
41. Huang J., et al. The same pocketin menin binds both MLL and JUND to produce opposite effects on transcription. Nature 2012, 482:542-546.
42. Murai M.J., et al. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J. Biol. Chem. 2011, 286:31742-31748.
43. Schnepp R.W., et al. Mutation of tumor suppressor gene Men1 acutely enhances proliferation of pancreatic islet cells. Cancer Res. 2006, 66:5707-5715.
44. Guru S.C., et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:1630-1634.
45. La P., et al. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene 2006, 25:3537-3546.
46. Jin S., et al. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Invest. 2010, 120:593-606.
47. Lemmens I.H., et al. Menin interacts directly with the homeobox-containing protein Pem. Biochem. Biophys. Res. Commun. 2001, 286:426-431.
48. Shi K., et al. The embryonic transcription factor Hlxb9 is a menin interacting partner that controls pancreatic beta-cell proliferation and the expression of insulin regulators. Endocr. Relat. Cancer 2013, 20:111-122.
49. Hughes C.M., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 2004, 13:587-597.
50. Yokoyama A., et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 2004, 24:5639-5649.
51. Agarwal S.K., et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999, 96:143-152.
52. Heppner C., et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001, 20:4917-4925.
53. Gang D., et al. The tumor suppressor protein menin inhibits NF-kappaB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma. Mol. Biol. Rep. 2012, 40:2461-2466.
54. Gurung B., et al. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res. 2013, 73:2650-2658.
55. Kim H., et al. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res. 2003, 63:6135-6139.
56. Kaji H., et al. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:3837-3842.
57. Bertolino P., et al. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res. 2003, 63:4836-4841.
58. Cao Y., et al. Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of {beta}-catenin. Mol. Cell. Biol. 2009, 29:5477-5487.
59. Chen G., et al. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol. Cancer Res. 2008, 6:1894-1907.
60. Veschi S., et al. Alterations of MEN1 and E-cadherin/beta-catenin complex in sporadic pulmonary carcinoids. Int. J. Oncol. 2012, 41:1221-1228.
61. Dreijerink K.M., et al. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 2006, 66:4929-4935.
62. Dreijerink K.M., et al. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. Mol. Cell. Biol. 2009, 29:5060-5069.
63. Yokoyama A., Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008, 14:36-46.
64. Scacheri P.C., et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2006, 2:406-419.
65. Wang P., et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 2009, 29:6074-6085.
66. Karnik S.K., et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14659-14664.
67. Milne T.A., et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:749-754.
68. Lin W., et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:13379-13386.
69. Thiel A.T., et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010, 17:148-159.
70. Thiel A.T., et al. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPalpha and differentiation in MLL-AF9 leukemia. Haematologica 2013, 98:918-927.
71. Lin C., et al. AFF4, a Component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37:429-437.
72. Okada Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
73. Grembecka J., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 2012, 8:277-284.
74. Shi A., et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012, 120:4461-4469.
75. Zhou H., et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. J. Med. Chem. 2013, 56:1113-1123.
76. Wu T., et al. Regulation of cyclin B2 expression and cell cycle G2/M transition by menin. J. Biol. Chem. 2010, 285:18291-18300.
77. Hernandez J.M., et al. Multiple facets of junD gene expression are atypical among AP-1 family members. Oncogene 2008, 27:4757-4767.
78. Agarwal S.K., et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10770-10775.
79. Martinelli D.C., Fan C.M. Gas1 extends the range of Hedgehog action by facilitating its signaling. Genes Dev. 2007, 21:1231-1243.
80. Luzi E., et al. The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases. Nucleic Acid Ther. 2012, 22:103-108.
81. Rulifson I.C., et al. Wnt signaling regulates pancreatic beta cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6247-6252.
82. Imachi H., et al. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res. Treat. 2010, 122:395-407.
83. Kim Y.S., et al. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 1999, 18:5936-5942.
84. Gallo A., et al. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 2002, 21:6434-6445.
85. Feng Z.J., et al. Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP beta/zeta signaling by menin. Oncogene 2010, 29:5416-5426.
86. Wang Y., et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res. 2011, 71:371-382.
87. Wuescher L., et al. Insulin regulates menin expression, cytoplasmic localization, and interaction with FOXO1. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E474-E483.
88. Hughes E., Huang C. Participation of Akt, menin, and p21 in pregnancy-induced beta-cell proliferation. Endocrinology 2011, 152:847-855.
89. Sowa H., et al. Menin inactivation leads to loss of transforming growth factor β inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res. 2004, 64:2222.
90. Mensah-Osman E., et al. Somatostatin stimulates menin gene expression by inhibiting protein kinase A. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295:G843-G854.
91. Zhang H., et al. Glucose-mediated repression of menin promotes pancreatic beta-cell proliferation. Endocrinology 2012, 153:602-611.
92. Luzi E., et al. The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit". PLoS ONE 2012, 7:e39767.
93. Francis J., et al. The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS ONE 2011, 6:e16119.
94. Busygina V., et al. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum. Mol. Genet. 2004, 13:2399-2408.
95. Suphapeetiporn K., et al. MEN1 tumor-suppressor protein localizes to telomeres during meiosis. Genes Chromosomes Cancer 2002, 35:81-85.